- Home
- HWC vs MRUS Comparison
HWC vs MRUS Comparison
Compare HWC & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWC
- MRUS
- Stock Information
- Founded
- HWC 1883
- MRUS 2003
- Country
- HWC United States
- MRUS Netherlands
- Employees
- HWC N/A
- MRUS N/A
- Industry
- HWC Major Banks
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- HWC Finance
- MRUS Health Care
- Exchange
- HWC Nasdaq
- MRUS Nasdaq
- Market Cap
- HWC 5.3B
- MRUS 5.1B
- IPO Year
- HWC N/A
- MRUS 2016
- Fundamental
- Price
- HWC $64.07
- MRUS $69.16
- Analyst Decision
- HWC Buy
- MRUS Strong Buy
- Analyst Count
- HWC 7
- MRUS 13
- Target Price
- HWC $67.86
- MRUS $92.15
- AVG Volume (30 Days)
- HWC 690.4K
- MRUS 619.9K
- Earning Date
- HWC 10-14-2025
- MRUS 10-30-2025
- Dividend Yield
- HWC 2.88%
- MRUS N/A
- EPS Growth
- HWC 27.47
- MRUS N/A
- EPS
- HWC 5.42
- MRUS N/A
- Revenue
- HWC $1,411,463,000.00
- MRUS $56,228,000.00
- Revenue This Year
- HWC $11.48
- MRUS $48.69
- Revenue Next Year
- HWC $5.56
- MRUS $3.15
- P/E Ratio
- HWC $11.55
- MRUS N/A
- Revenue Growth
- HWC 8.24
- MRUS 59.77
- 52 Week Low
- HWC $43.90
- MRUS $33.19
- 52 Week High
- HWC $64.62
- MRUS $70.65
- Technical
- Relative Strength Index (RSI)
- HWC 61.98
- MRUS 59.06
- Support Level
- HWC $61.83
- MRUS $66.49
- Resistance Level
- HWC $64.66
- MRUS $69.63
- Average True Range (ATR)
- HWC 1.14
- MRUS 2.46
- MACD
- HWC -0.06
- MRUS -0.05
- Stochastic Oscillator
- HWC 79.81
- MRUS 83.54
About HWC Hancock Whitney Corporation
Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.